-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

A Treatment Option for Adult Patients with Newly Diagnosed CP Ph+ CML or Patients with CML Resistant/Intolerant to Prior TKI Therapy

Program: Product Theaters
Session: A Treatment Option for Adult Patients With Newly Diagnosed CP Ph+ CML or Patients With CML Resistant/Intolerant to Prior TKI Therapy
Sunday, December 6, 2020, 11:00 AM-12:00 PM

Jasmeet Anand, PharmD

Pfizer, New York, NY

Disclosures: No relevant conflicts of interest to declare.

See more of: A Treatment Option for Adult Patients With Newly Diagnosed CP Ph+ CML or Patients With CML Resistant/Intolerant to Prior TKI Therapy
See more of: Product Theaters